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Over the last 30 years there have been tremendous advances in CHO cell culture process engineering. Novel 
process concepts, such as fed batch, perfusion and continuous cultures, evolved from a deep understand of 
CHO metabolic needs and extensive media/feed formulation development. This knowledge has led to large 
gains in protein productivity that can be captured with culture duration and/or scale. The biotechnology industry 
is consistently pressured to reduce cost of manufacturing and improve per batch productivity. Independent, but 
related to this burden, is the ability to support an ever growing patient population with high doses of therapeutic 
protein. As such, Biogen partnered with MIT to take a holistic view of the potential future of biomanufacturing to 
identify technologies that can make step changes in productivity and cost reduction. These efforts have cast 
doubt that CHO would be the optimal host in the future, whereas a non-mammalian host could be a key to 
realizing the most significant gains in productivity and reduction in cost of manufacturing.  
 
Recombinant antibody production from non-mammalian hosts has been reported in the past, for example from 
the yeast pichia and filamentous fungi Trichoderma, and antibody material produced from pichia has been used 
in clinical trials.  In the next phase of this initiative, we sought to take a more comprehensive approach to 
investigate alternative hosts in recombinant antibody production. Eight non-mammalian hosts were selected 
based on a number of properties, including proven secretion of recombinant protein products, ability to 
glycosylate proteins, established genome or molecular biology toolkit, amongst other characteristics. We 
designed an experimental plan that would enable more straightforward comparative analysis between hosts and 
included two main criteria to maintain a level playing field. First, only non-engineered, wild-type strains would be 
used as a starting point for all eight hosts of interest. Second, a single IgG1 model antibody was selected to be 
expressed by all hosts. In this presentation, the outcome of this comparative analysis will be discussed, 
including productivity values and details of the model antibody product quality. Based on this data the most 
productive strains will be made available for use without restrictions to allow others in the community to freely 
work with these hosts. 
 
 
 
